Quantcast

Latest Clinical research Stories

2014-08-19 08:30:53

MALVERN, Pa., Aug. 19, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products for the treatment of pain, announced that it had formed a Scientific Advisory Board composed of four members: Dr. Jeff Gudin, Dr. Charles Argoff, Dr. Srinivas Nalamachu and Mr. Kip Vought. SCILEX Chief Executive Officer Anthony Mack said the expertise of this board would greatly assist in the development and...

2014-08-19 08:30:32

GLEN BURNIE, Md., Aug. 19, 2014 /PRNewswire/ -- CSSi, the leader in patient recruitment solutions for the clinical research industry, recently announced the formation of the company's Medical and Clinical Advisory Board ("MCAB") and is pleased to announce the addition of Dr. William E. Gannon, Jr. to the MCAB. Photo - http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. Gannon's leadership, will help provide insight across a variety of therapeutic areas and set...

2014-08-19 08:30:02

BELLEVILLE, ON, Aug. 19, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today announced that it is targeting Q1/2015 for the filing of a Biologics License Application (BLA) with the United States Food and Drug Administration (FDA) for Bioniche's lead program Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) for the treatment of patients with high grade non-muscle invasive bladder cancer that have failed Bacillus Calmette-Guérin (BCG) therapy. This projected timeline...

2014-08-18 23:09:50

On August 11, the FDA advised consumers not to purchase or use Arize due to undeclared drug ingredient. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) August 18, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Arize. The US FDA advised consumers on August 11, not to purchase or use Arize because it...

2014-08-18 16:28:18

Second Phase 3 Registrational Study Meets Primary and All Secondary Endpoints THOUSAND OAKS, Calif., Aug. 18, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent...

2014-08-18 16:23:29

LONDON, Aug. 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Inflammatory Skin Diseases-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278593/-Inflammatory-Skin-Diseases-Pipeline-Insights-2014.html SUMMARYDelveInsight's," Inflammatory Skin Diseases-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the...

2014-08-18 16:23:26

LONDON, Aug. 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Impetigo-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278589/-Impetigo-Pipeline-Insights-2014.html SUMMARYDelveInsight's," Impetigo-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Impetigo. This report...

2014-08-18 12:27:56

ELLICOTT CITY, Md., Aug. 18, 2014 /PRNewswire/ -- The Society for Clinical Research Sites (SCRS), the trade organization representing over 1,500 clinical research sites in 37 countries, today announced INC Research, a leading, global Phase I to IV clinical research organization (CRO), will sponsor site appreciation events at the society's annual Site Solutions Summit, Oct. 10-12, 2014, on Amelia Island, Fla. and its inaugural European Summit, March 25-27, 2015, in Croatia. "We are...

2014-08-18 12:27:06

Funding Announcement Includes Three New Topic Areas of Interest WASHINGTON, Aug. 18, 2014 /PRNewswire-USNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) today issued the third funding announcement under its Pragmatic Clinical Studies initiative, offering up to $90 million in support for studies that address practical comparative questions faced by patients, clinicians, and other healthcare decision makers. PCORI will provide up to $10 million in direct costs for studies...

2014-08-18 08:28:40

SHANGHAI, Aug. 18, 2014 /PRNewswire/ -- WuXiPharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that a manufacturing facility of WuXi's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA) passed an FDA inspection in July for the manufacture of the active pharmaceutical ingredient (API) for a branded commercial drug. This...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'